PT-141 (Bremelanotide) and Hormonal Contraceptives: What Clinicians and Patients Should Know

How Bremelanotide Works and Why It Matters for Co-Prescribed Drugs

Bremelanotide is a melanocortin-4 receptor (MC4R) agonist administered as a 1.75 mg subcutaneous injection. It activates central nervous system pathways involved in sexual desire without directly affecting reproductive hormones like estrogen or progesterone [1]. This distinction is important: bremelanotide does not compete with, suppress, or amplify the hormonal mechanisms that contraceptives rely on.

The drug's interaction profile is narrow. In vitro studies submitted to the FDA showed that bremelanotide does not meaningfully inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at therapeutic concentrations [1]. Since combined oral contraceptives (COCs) depend on CYP3A4 for ethinyl estradiol metabolism, the absence of CYP3A4 interference means bremelanotide does not change how the body processes contraceptive hormones once they reach the bloodstream.

The real concern is not metabolism. It is absorption. Bremelanotide triggers a transient slowing of gastric emptying, a known class effect of melanocortin agonists. This delays the transit of anything sitting in the stomach, including an oral contraceptive pill taken too close to the injection [2]. The effect is time-limited, peaking within the first 1 to 2 hours after injection and resolving as bremelanotide's plasma concentration falls (half-life approximately 2.7 hours) [1].

The FDA's Specific Warning on Oral Contraceptive Absorption

The Vyleesi prescribing information includes a dedicated subsection on this interaction. The label states it plainly: co-administration with oral medications, including oral contraceptives, may result in decreased absorption rate and delayed time to peak concentration.

In a pharmacokinetic sub-study conducted during the RECONNECT trials, women receiving bremelanotide 1.75 mg alongside a standard COC showed an approximate 20% reduction in Cmax for ethinyl estradiol and a measurable delay in Tmax [1]. The total exposure (AUC) was not significantly reduced, meaning the hormones were still absorbed in full but more slowly. This is a rate-of-absorption effect, not a total-absorption effect.

The practical consequence: if a woman takes her pill and injects bremelanotide within a short window, the contraceptive's peak blood level arrives later and lower than expected. For most women on a steady-state regimen, this single-dose blunting is unlikely to cause contraceptive failure. But the FDA's conservative recommendation is to separate the two by at least one hour, with the oral contraceptive taken first [1].

"This is a GI motility interaction, not a hormonal one," notes the FDA clinical pharmacology review for Vyleesi (NDA 210557). "The recommendation to pre-dose the oral contraceptive by at least one hour is a practical buffer that preserves the rate-limited absorption window" [2].

Which Contraceptive Methods Are Affected (and Which Are Not)

Not all hormonal contraceptives pass through the GI tract. The interaction with bremelanotide is limited to formulations that require oral absorption. Here is a breakdown by method:

Affected (oral route):

• Combined oral contraceptives (ethinyl estradiol + progestin)
• Progestin-only pills (norethindrone, drospirenone-only)

Not affected (bypass GI absorption):

• Levonorgestrel IUD (Mirena, Liletta, Kyleena, Skyla)
• Copper IUD (Paragard, which is non-hormonal and irrelevant to this interaction)
• Etonogestrel implant (Nexplanon)
• Medroxyprogesterone acetate injection (Depo-Provera)
• Norelgestromin/ethinyl estradiol patch (Xulane)
• Etonogestrel/ethinyl estradiol vaginal ring (NuvaRing, Annovera)

Women using any non-oral method can take bremelanotide without timing adjustments [1]. For the roughly 26% of U.S. contraceptive users who rely on the pill, per CDC data from the National Survey of Family Growth [3], the one-hour separation rule applies.

Pharmacokinetic Details: What the Numbers Show

The interaction data come from a dedicated drug-drug interaction study described in the FDA's clinical pharmacology review for bremelanotide (NDA 210557). The study enrolled healthy premenopausal women on a stable COC regimen containing 30 mcg ethinyl estradiol and 150 mcg levonorgestrel [2].

Key findings from this study:

• Ethinyl estradiol Cmax decreased approximately 20% when the COC was taken with bremelanotide versus alone
• Ethinyl estradiol Tmax shifted from a median of 1.5 hours to approximately 2.5 hours
• Ethinyl estradiol AUC(0-inf) showed no statistically significant change, confirming total absorption was preserved
• Levonorgestrel Cmax decreased approximately 11%, with a similar Tmax delay
• Levonorgestrel AUC remained within the 80% to 125% bioequivalence bounds

These numbers explain why the FDA classified this as a mild interaction rather than a contraindication. The hormones still get absorbed. They just arrive late [2]. A single delayed peak on a background of daily steady-state dosing has minimal clinical impact on ovulation suppression, which depends on sustained hormone levels rather than any single peak.

Clinical Monitoring and Dose-Adjustment Guidance

No dose adjustment is needed for either bremelanotide or the hormonal contraceptive [1]. The management strategy is purely about timing.

Prescribers should counsel patients on these points:

1. Take the oral contraceptive pill at least one hour before injecting bremelanotide
2. If the pill was already taken less than one hour before, the single-dose absorption delay is minor and does not warrant emergency contraception
3. Women who find the timing separation inconvenient may consider switching to a non-oral contraceptive method, which eliminates the interaction entirely
4. Bremelanotide itself is dosed on an as-needed basis (not daily), so this interaction only occurs on days the injection is used
5. The maximum recommended frequency is 1 injection per 24 hours, with a cap of 8 injections per month [1]

Blood pressure monitoring deserves a separate mention. Bremelanotide causes a transient increase in systolic blood pressure of approximately 6 mmHg, peaking at about 2 to 3 hours post-injection, according to pooled RECONNECT data [4]. Combined oral contraceptives also carry a small BP-elevating effect. While no additive signal was identified in the clinical program, women with baseline blood pressure above 130/80 mmHg should have their pressure checked when starting either drug and at follow-up visits [5].

RECONNECT Trials: Safety in the Target Population

The RECONNECT phase III program (two replicate trials, RECONNECT-1 and RECONNECT-2) enrolled 1,247 premenopausal women with HSDD, a population where hormonal contraceptive use is common [4]. In these trials, approximately 40% of participants were using some form of contraception, including oral pills, IUDs, and implants.

The pooled safety data showed no signal of unintended pregnancy attributable to a bremelanotide-contraceptive interaction. Across both trials, the pregnancy rate was consistent with the expected failure rate of the contraceptive methods used by enrollees [4]. The most common adverse events were nausea (40%), flushing (20%), and headache (11%), none of which are hormonally mediated or suggestive of contraceptive interference [1].

A post-hoc subgroup analysis published in the Journal of Sexual Medicine found no difference in efficacy or adverse event rates between women using oral contraceptives and those using non-oral methods [6]. Both groups showed a mean increase of 0.6 on the FSDS-DAO (Female Sexual Distress Scale, Desire/Arousal/Orgasm) desire domain, suggesting the drug works the same regardless of contraceptive choice.

Progestin-Only Pills Deserve Extra Attention

Progestin-only pills (POPs, sometimes called the "mini-pill") have a narrower dosing window than combined pills. Traditional norethindrone-based POPs must be taken within the same 3-hour window daily to maintain contraceptive efficacy [7]. The newer drospirenone-only pill (Slynd) has a wider 24-hour window but still depends on oral absorption [8].

For POP users, the bremelanotide interaction carries slightly more practical weight. A delayed Cmax on a drug with an already tight pharmacokinetic margin means the one-hour separation rule should be followed strictly. Women who use bremelanotide frequently (approaching the 8-dose monthly cap) and find the timing difficult to manage should discuss switching to an IUD or implant with their provider.

No dedicated pharmacokinetic study of bremelanotide plus a POP has been published. The FDA label generalizes its warning to all "oral medications," which by default includes POPs [1]. Until specific data emerge, the conservative approach is appropriate.

What About Emergency Contraception?

Levonorgestrel emergency contraception (Plan B, Take Action) is a single high-dose oral tablet. If a woman takes bremelanotide and then needs emergency contraception within the next few hours, the gastric-emptying delay could theoretically slow absorption of the levonorgestrel pill. No clinical data address this specific scenario.

A practical workaround: ulipristal acetate (ella) is an alternative emergency contraceptive that is equally effective and may be less sensitive to modest absorption delays given its longer half-life (approximately 32 hours) and wider Tmax range [9]. The copper IUD, the most effective form of emergency contraception (failure rate <0.1%), bypasses the GI tract entirely and is unaffected by bremelanotide [10].

Other Drug Interactions Worth Knowing

While this article focuses on hormonal contraceptives, bremelanotide carries a few other interaction considerations that prescribers managing premenopausal women should keep in mind.

Naltrexone: Co-administration with naltrexone 50 mg reduced bremelanotide's efficacy by approximately 25% in a PK/PD study. The FDA label recommends against combining the two [1].

Oral medications generally: The gastric-emptying effect applies to any oral drug, not just contraceptives. Medications with narrow therapeutic indices (warfarin, levothyroxine, anti-epileptics) should be taken at least one hour before bremelanotide [1].

Antihypertensives: Given the transient BP increase, additive monitoring is warranted when bremelanotide is used alongside ACE inhibitors, ARBs, or beta-blockers, though no formal dose adjustment is required [5].

Alcohol: The RECONNECT trials did not exclude moderate alcohol use, and no specific ethanol-bremelanotide interaction was identified. Nausea is more common with bremelanotide, though, and alcohol may worsen it [4].